CC-94676 for Prostate Cancer

Phase-Based Progress Estimates
University Of Chicago, Chicago, ILProstate CancerCC-94676 - Drug
What conditions do you have?

Study Summary

This trial is testing a new drug for men with prostate cancer that has spread and is resistant to hormone therapy.

Eligible Conditions
  • Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

8 Primary · 20 Secondary · Reporting Duration: Up to approximately 4 years

Day 28
Adverse Events (AEs)
Number of participants with adverse events (AEs) evaluated using the NCI CTCAE v5.0 criteria
Up to 35 days
Dose-limiting Toxicities (DLTs)
Dose-limiting toxicity (DLT)
Maximum Tolerated Dose (MTD)
Maximum tolerated dose (MTD)
Non-Tolerated Dose (NTD)
Non-tolerated dose (NTD)
Pharmacokinetics - AUC
Pharmacokinetics - Area under the plasma concentration time curve (AUC)
Pharmacokinetics - CL/F
Pharmacokinetics - Cmax
Pharmacokinetics - Maximum plasma concentration (Cmax)
Pharmacokinetics - Time to Cmax (Tmax)
Pharmacokinetics - Tmax
Pharmacokinetics - Vz/F
Pharmacokinetics - t1/2
Month 6
Proportion of participants alive and not progressed at 6 months
Proportion of subjects alive and not progressed at 6 months
Year 4
Complement H50
Duration of response (DOR)
Objective soft tissue response
Objective soft tissue response defined by complete response (CR) or partial response (PR) per Prostate Cancer Clinical Trials Working Group 3 (PCWG3)
Overall Survival (OS) rate
Overall Survival (OS) rate summarized using the Kaplan-Meier method for the treated population
Overall survival (OS)
PSA Progression Free Survival (PFS)
Radiographic progression free survival (rPFS)

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

1 Treatment Group

Administration of CC-94676
1 of 1

Experimental Treatment

122 Total Participants · 1 Treatment Group

Primary Treatment: CC-94676 · No Placebo Group · Phase 1

Administration of CC-94676
Experimental Group · 1 Intervention: CC-94676 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 4 years

Who is running the clinical trial?

CelgeneLead Sponsor
625 Previous Clinical Trials
122,997 Total Patients Enrolled
5 Trials studying Prostate Cancer
1,270 Patients Enrolled for Prostate Cancer
Marie Nguyen, MDStudy DirectorCelgene
3 Previous Clinical Trials
141 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,416 Previous Clinical Trials
3,311,189 Total Patients Enrolled
14 Trials studying Prostate Cancer
4,383 Patients Enrolled for Prostate Cancer

Eligibility Criteria

Age 18+ · Male Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

To what extent has recruitment for this clinical experiment been successful?

"This medical trial necessitates 122 participants that meet the qualifications. Potential volunteers can join from Sibley Memorial Hospital in Washington, D.C., and UAB in Birmingham, Alabama." - Anonymous Online Contributor

Unverified Answer

Is CC-94676 a reliable option for patient treatment?

"The safety of CC-94676 is rated as 1 due to its current Phase 1 status; this signifies that only limited data exists for both efficacy and safety." - Anonymous Online Contributor

Unverified Answer

Is the enrollment period for this trial still open?

"The database confirms that this medical trial is recruiting patients at present, with the original post dated June 22nd 2020 and the last editing occuring on December 1st 2022." - Anonymous Online Contributor

Unverified Answer

How widespread are the implementations of this experiment in Canada?

"Sibley Memorial Hospital in Washington D.C., UAB in Birmingham, Alabama and Florida Cancer Specialists in Sarasota, FL are all hosting participating sites for this medical trial alongside 23 other clinical locations." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.